Valuation dashboard for Supernus Pharmaceuticals, Inc. (SUPN) with P/E N/A, P/B 2.41, EV/EBITDA -147.59 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention.
Analysis Summary
Supernus Pharmaceuticals, Inc. reported revenue of $719.0M in the most recent fiscal year, growing at a 5-year CAGR of 6.7%.
Trailing-twelve-month margins: gross margin 88.1%, operating margin -13.5%, net margin -13.2%.
At the current price of $43.04, SUPN has negative trailing earnings (P/E not meaningful) and an ROE of -10.42%. Market capitalisation stands at $2.5B.
Balance sheet quality for SUPN: current ratio of 1.9. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 2.41 |
| EV / EBITDA | -147.59 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $89.18 |
| vs Current Price | +107.2% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| SUPN | Supernus Pharmaceuticals, Inc. | $2.5B | 2.41 | -10.4% | |
| CNTA | Centessa Pharmaceuticals plc | $6.3B | 12.76 | -37.5% | |
| CGON | CG Oncology Inc. | $6.2B | 5.66 | -25.2% | |
| LNTH | Lantheus Holdings, Inc. | $6.5B | 23.79 | 4.97 | 23.3% |
| AMRX | Amneal Pharmaceuticals, Inc. | $6.5B | 40.85 | 196.46 | -326.8% |
| INDV | Indivior Pharmaceuticals Inc | $4.5B | 12.57 | -214.3% | |
| HCM | HUTCHMED (China) Limited | $2.5B | 155.01 | 1.97 | 37.0% |
| GRAL | GRAIL Inc. | $5.7B | 2.51 | -15.9% |
Price
| Price | $43.04 |
| Market Cap | $2.5B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -10.42% |
| Return on Invested Capital | -9.12% |
| Return on Assets | -7.69% |
| Gross Margin | 88.07% |
| Operating Margin | -13.46% |
| Net Margin | -13.23% |
Related companies: AMRX · BHC · CGON · GRAL · HCM · INDV
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of SUPN: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks